Skip to main content

Table 1 Clinicopathological characteristics of the studied population

From: The high methylation level of a novel 151-bp CpG island in the ESR1 gene promoter is associated with a poor breast cancer prognosis

  Case Control P
n (%) n (%)
Cancer family history
 Yes 24 (63.16) 7 (40.0) 0.0410*
 No 14 (36.84) 13 (60.0)
  n (%), age+ n (%), age+  
Menopause
 Premenopause 12 (31.6) 41.33 ± 5.97 15 (75.0) 34.80 ± 12.42 0.0016*
 Postmenopause 26 (68.4) 57.58 ± 12.56 5 (25.0) 49.60 ± 20.21
Cancer stage grouping
 I 1 (2.6) NA  
 II 18 (47.4) NA  
 III 15 (39.5) NA  
 IV 4 (10.5) NA  
Phenotype
 Luminal/HER2+ 11 (28.9) NA  
 HER2+ 11 (28.9) NA  
 Luminal A 4 (10.5) NA  
 Mixed phenotypea 7 (18.4) NA  
 Triple-negative 5 (13.2) NA  
  Case, n (%) Control, n (%) P
Immunohistochemical profileb
 Estrogen receptor (ER) Positive Negative  
 Triple-negative 19 (50.0) 19 (50.0) NA
 Progesterone receptor 18 (47.4) 20 (52.6) NA
 HER2+ 26 (68.4) 12 (31.6) NA
  1. NA not applicable, n sample size
  2. P = statistically significant value was considered as P < 0.05 using Chi-square test
  3. aPopulation expressing both: and estrogen receptor or progesterone receptor
  4. bComparative analysis into case group only